Array Biopharma (ARRY) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
Revenue Growth %: -16.4%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -16.4%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.11 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $32.7 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- UBS Downgrades Array Technologies (ARRY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
